Skip to main content

Advertisement

We’d like to understand how you use our websites in order to improve them. Register your interest.
Download PDF

The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: a 4-week, open-label trial

Arthritis Research & Therapy volume 18, Article number: 195 (2016) Cite this article

Abstract

Background

Acute administration of the oral 5-HT1A receptor agonist buspirone, which is commonly used as an anxiolytic drug, may improve compromised lower esophageal sphincter function. In an open-label trial we assessed the effects of buspirone on esophageal motor function and symptoms in patients with esophageal involvement associated with systemic sclerosis (SSc).

Methods

Thirty consecutive patients with SSc and symptomatic esophageal involvement, despite treatment with proton pump inhibitors, underwent high resolution manometry and chest computed tomography for assessment of motor function and esophageal dilatation, respectively. Regurgitation, heartburn, dysphagia, and chest pain severity was subjectively scored by visual analog scales. Manometric parameters (primary endpoint) and symptom severity (secondary endpoint) were re-examined after 4-week daily administration of 20 mg buspirone. Other medications remained unchanged.

Results

Eight patients did not complete the trial because of buspirone-associated dizziness (n = 2), or nausea (n = 2), or reluctancy to undergo final manometry. In the remaining 22 patients lower esophageal sphincter (LES) resting pressure increased from 7.7 ± 3.9 to 12.2 ± 4.6 mmHg (p = 0.00002) after buspirone administration; other manometric parameters did not change. Statistical analysis revealed negative correlation between individual increases in resting LES pressure and supra-aortic esophageal diameter (r = -0.589, p = 0.017), suggesting a more beneficial effect in patients with less severely affected esophageal function. Heartburn and regurgitation scores decreased at 4 weeks compared to baseline (p = 0.001, and p = 0.022, respectively).

Conclusion

Our findings warrant more conclusive evaluation with a double-blind controlled study; however, buspirone could potentially be given under observation for objective improvement in all patients with SSc who report reflux symptoms despite undergoing standard treatment.

Trial registration

ClinicalTrials.gov Identifier: NCT02363478 Registered: 21-02-2014.

Background

Systemic sclerosis (SSc) is a chronic autoimmune fibrotic disease affecting the skin and other organs including the gastrointestinal tract. The esophagus is commonly affected in SSc and esophageal function is compromised in up to 90 % of patients [1, 2]. Symptoms of esophageal disease are due to gastroesophageal reflux disease (GERD) and esophageal motor dysfunction. Thus, heartburn, regurgitation and dysphagia have been reported by 80 % of patients with SSc [3, 4].

Although several medications are used in patients with symptomatic SSc and esophageal involvement, there is no universally effective treatment. The current therapeutic approach includes administration of proton pump inhibitors (PPIs) and prokinetics agents (including metoclopromide, erythromycin, cisapride and domperidone), although the evidence to support their use is limited [5]. It is well-known that there are many issues in the efficacy and long-term use of the currently available prokinetic drugs; use of metoclopromide or erythromycin or cisapride is restricted due to safety profile issues and administration route problems, while administration of domperidone has no effect on esophageal motor dysfunction in patients with symptomatic SSc [6].

Animal studies have identified serotonin (5-hydroxytryptamine, 5-HT) as one of the putative neurotransmitters involved in esophageal motor function making its receptors suitable therapeutic targets [7]. Studies in healthy volunteers show that acute administration of buspirone, a 5-HT1A receptor agonist, has a strong stimulatory effect on esophageal peristalsis and lower esophageal sphincter (LES) function [8, 9]. Moreover, we have recently observed that acute administration of buspirone exerts a beneficial effect on esophageal motor dysfunction associated with SSc [6]. Thus, in order to investigate whether buspirone exerts a long-term effect in SSc-associated esophageal involvement we conducted a prospective 4-week open-label trial. The primary objective was to assess the efficacy of buspirone on LES dysfunction. The secondary efficacy endpoint was change in esophageal symptoms after buspirone administration.

Methods

Study population

Thirty consecutive consenting patients who fulfilled classification criteria for SSc [10] and were able to perform high resolution manometry (HRM) participated in this open-label, non-randomized study. The only inclusion criterion was the presence of symptoms associated with esophageal involvement, such as regurgitation, heartburn, dysphagia, and chest pain, despite standard treatment with PPIs. These symptoms were scored on a 100-point visual analog scale (VAS) ranging from 0 (absent) to 100 (very severe)..Other types of esophageal diseases that could explain patients’ symptoms were excluded because all patients had undergone gastroscopy in the past.

Eight patients did not complete the study; 4 patients reported adverse effects with buspirone administration (2 dizziness and 2 nausea) and 4 patients were reluctant to perform the second HRM examination. The remaining 22 patients (aged 52.5 ± 11.6 years, 19 women) were re-examined after 4 weeks. During the study period all patients continued their therapy unchanged, including administration of proton pump inhibitors. All patients were on single PPIs dose before and during the study period and none was on medications that could affect results, such as prokinetics or erythromycin.

Before proceeding to esophageal manometry studies all patients filled out a self-reported symptom questionnaire in order to assess the severity of esophageal symptoms. Severity of dysphagia, heartburn, regurgitation, and chest pain was measured on a VAS (0–100). The VAS score has been adopted in many other trials for evaluation of visceral symptoms and has been used as a tool for self-assessment of symptoms [11, 12], and any decrease in the score at week 4 versus baseline was considered an improvement. Demographic data and phenotypic characteristics of the disease were collected from the clinical charts. Moreover, in all patients the supra-aortic and infra-aortic coronal diameters of the esophagus were measured in chest computed tomography (CT) performed within the previous 3 months. Esophageal dilatation was deemed present when the diameter was >9 mm [13]. The study protocol was approved by the ethics committee of “Laikon” General Hospital and informed consent was obtained from all participating patients.

High resolution manometry

All patients were fasted and were studied in the supine position. Esophageal manometry was performed with a water-perfused assembly with 22 pressure sensors (Solar GI HRM, MMS, Enschede, The Netherlands). The HRM catheter was passed trans-nasally and positioned to record from the hypopharynx to the stomach. The catheter was fixed in place by taping it to the nose. The manometric examination included a 30-sec period to assess basal LES pressure and 10 swallows of 5 mL water. Double swallows were discarded and these were repeated. The study was repeated 4 weeks after oral administration of 20 mg buspirone (10 mg twice a day). We recorded 1) amplitude, duration and velocity of contractions at the distal part of the esophagus (defined as the mean amplitude at 3 and 8 cm proximal to the LES upper border of the esophagus) and 2) resting and residual LES pressure and integrated relaxation pressure (IRP). The LES pressures were referenced to intragastric pressure and we reported the mean resting pressure values.

All HRM tracings were interpreted by the same investigator (GK), who was blinded to whether administration of buspirone was performed. Hypotensive LES was considered when LES resting pressure was ≤10 mmHg, whereas isobaric contour <20 mmHg was considered as the cutoff for esophageal hypomotility [14].

Statistical methods

The paired-sample t test was used to compare changes from baseline in manometric values and severity of symptoms after buspirone administration, as all data analyzed were normally distributed. The Spearman correlation coefficient was used to assess the relationship between increase in LES pressure and other clinical, manometric, and CT parameters, because of non-canonical data distribution. Values were expressed as mean ± SD. A p value <0.05 was considered significant.

Results

Table 1 summarizes demographic characteristics, expression and duration of disease, CT, baseline manometry, and severity of esophageal symptoms. The mean amplitude of distal esophageal contractions was 16.6 ± 9.6 mmHg, whereas esophageal hypomotility was identified in 19 patients (86 %). The mean resting pressure of the LES was 7.7 ± 3.9 mmHg, whereas a hypotensive LES was observed in 17 patients (77 %). Both esophageal body and LES abnormalities were found in 16 patients (73 %). According to the Chicago classification 16 patients had absent peristalsis, 5 patients had weak peristalsis and 1 patient had normal esophageal motility. On chest CT 12 patients (54.5 %) had supra-aortic esophageal dilatation, whereas almost all patients had infra-aortic esophageal dilatation (21/22, 95.5 %).

Table 1 Demographic characteristics, disease characteristics, symptoms, and manometry in the study population (n = 22)
Full size table

Heartburn and regurgitation were reported by almost all patients (91 % and 86 %, respectively), while dysphagia was reported by 54.5 % of patients. Only 36 % of patients reported chest pain as one of their symptoms. Moreover, regurgitation and heartburn were the most bothersome symptoms reported to a similar extent, followed by dysphagia and chest pain (Table 1).

Effect of buspirone on manometric parameters

Following buspirone administration for 4 weeks the LES resting pressure significantly increased from 7.7 ± 3.9 to 12.2 ± 4.6 mmHg (p < 0.00005). Figure 1 increased LES resting pressure after buspirone administration was observed in 15 patients (68 %) with a range of 4–13 mmHg (41–220 %, accordingly). There were significantly fewer patients with hypotensive LES after compared to before buspirone administration (8/22 vs. 17/22, respectively, p = 0.006).

Fig. 1
figure1

Change in lower esophageal sphincter (LES) pressure in each individual at baseline and after 4-week daily oral administration of 20 mg buspirone

Full size image

In contrast to LES resting pressure, buspirone administration had no effect on LES residual pressure or on IRP (Table 2). In addition, buspirone administration did not increase the duration and velocity of esophageal body contractions or the amplitude of contractions, compared to baseline values (Table 2). Buspirone was well-tolerated by all patients who completed the study.

Table 2 Manometric parameters at baseline and after 4-week daily administration of 20 mg buspirone
Full size table

Correlation between individual increase in LES pressure and other clinical, manometric and CT parameters

Table 3 summarizes the correlation between individual increase in LES pressure and other variables. There was moderate, but significant, inverse correlation between increased LES resting pressure and supra-aortic diameter (p = 0.017). The Pearson correlation coefficient was an r value of -0.589. In patients without supra-esophageal dilatation there was greater improvement in LES pressure (83.9 ± 38.1 % vs.19.2 ± 26.8 %, p = 0.037). There was no significant correlation between increased LES pressure and other measured parameters.

Table 3 Correlation between increase in LES pressure after 4-week daily administration of 20 mg buspirone and clinical, manometric and computed tomography parameters
Full size table

Effect of buspirone on esophageal symptoms

The severity of regurgitation and heartburn significantly decreased from baseline following buspirone administration for 4 weeks (39.3 ± 29.8 vs. 24.4 ± 22.0, p = 0.02 and 37.1 ± 23.9 vs. 21.9 ± 21.2, p = 0.001, respectively). There was no significant improvement in the scores for severity of chest pain and dysphagia (10.4 ± 23.1 vs. 8.5 ± 20.0 and 25.8 ± 30.7 vs. 18.9 ± 21.9, p = 0.203, respectively).

Improvement in the severity of heartburn was reported by 70 % (14/20) of patients who had heartburn at baseline, while 58 % (11/19) of patients with regurgitation at baseline had improvement in the severity of regurgitation. Increased LES resting pressure was simultaneously observed in the majority of patients with improvement in heartburn and regurgitation (12/14 and 8/11, respectively). Half of the patients with baseline dysphagia reported improvement in their symptom severity, while a minority of patients (25 %) with baseline chest pain had an improvement in the severity of their symptoms.

Discussion

Treatment of patients with symptomatic SSc and esophageal involvement is still an area of unmet need, as there is no available treatment with established efficacy. Administration of PPIs and prokinetic drugs do not appear to provide substantial symptomatic relief in patients with SSc and esophageal symptoms [5]. Pathophysiology of gastrointestinal dysmotility in SSc is multifactorial and different neurotransmitters could be involved in this process [15, 16]. Serotonin (5-HT) is considered a key neurotransmitter and acute studies, both in healthy subjects and patients with SSc, have shown that agonists of specific class of its receptors, such as 5-HT1A, could be a putative therapeutic option [6, 8, 9]. Buspirone had been initially developed for clinical use in the treatment of depression and anxiety disorders. Its mechanisms of action are thought to include agonistic actions, mainly on 5-HT1A receptors, but also on dopamine D2 receptors. Buspirone is absorbed rapidly and almost completely with a tmax = 0.89 ± 0.15 h [17].

To the best of our knowledge no previous study has prospectively investigated whether a pharmaceutical agent may help patients with SSc and esophageal involvement. The results of our open-label, prospective 4-week trial suggest that the 5-HT1A receptor agonist, buspirone, given orally for 4 weeks, significantly increases the LES resting pressure by 41 % to 220 % over the baseline values in almost 70 % of patients with SSc. Furthermore, patients with a less dilated esophagus as detected on chest CT had a better response to buspirone administration. This is an important aspect of our study, as patients with SSc undergo routine chest CT as a screening test for lung fibrosis. Many studies have suggested that measurement of esophageal coronal diameter on chest CT is a marker of the functional status of the esophagus in SSc and a dilated esophagus represents more severe visceral involvement [18, 19].

Herein, the 4-week administration of buspirone also alleviated heartburn and regurgitation in the majority of patients. Buspirone seems more effective for GERD-related symptoms, whereas symptoms related to esophageal hypomotility, such as dysphagia and chest pain are not affected. Thus, we could suggest that buspirone administration may be most helpful for the subgroup of SSc patients with reflux symptoms. An objective assessment of reflux response with pH-impedance measurement could certainly enhance our results.

As all patients were on PPIs before and during the study period, the strategy with add-on buspirone could be a worthwhile therapeutic option. Keeping in mind the anecdotal evidence that persistent reflux contributes significantly to the development of interstitial lung disease and/or progress, which is the leading cause of death in SSc, the potential beneficial effect of buspirone becomes more important. Buspirone-associated improvement in the severity of reflux symptoms can be explained by a strong stimulatory effect on LES resting pressure. However, other mechanisms cannot be excluded. Comorbid psychiatric diseases in patients with a chronic disorder, such as SSc, and especially anxiety, are common [20, 21]. Buspirone is used as anxiolytic drug in clinical practice. Therefore, a potential alteration in the sensitivity by decreasing the anxiety level may play a role in symptom improvement. As we did not include measurement of anxiety scores, this is a limitation of the present study. However, in the event that the main mechanism underlying symptom improvement with buspirone was the anxiolytic effect of the drug, other non-reflux symptoms should have been improved.

A limitation of the present study, due to restrictive regulatory rules that we were unable to overcome, is that it is not a randomized, placebo-controlled investigation and there is a lack of a control arm. Another limitation is the relatively small number of patients studied; however, we have to keep in mind that patients with SSc due to the chronic nature of their disease have several medical disabilities, making recruitment very challenging. The use of a validated questionnaire, such as the UCLA STCC SSc-GI [22] rather than a self-reported one could strengthen our results, however, this questionnaire, which covers a broad spectrum of gastrointestinal symptoms in patients with SSc, is not validated in Greek. Moreover, the majority of available questionnaires are focused on reflux symptoms rather than on dysmotility-associated symptoms characterizing SSc.

Buspirone was well-tolerated in the present study. Treatment interruption due to adverse effects (dizziness and nausea) was observed in only 4 out of 30 patients. Patients who completed the study reported sporadic and self-limited adverse effects that did not affect their daily activities.

Conclusions

In conclusion, our study showed that 4-week daily administration of buspirone increases the LES resting pressure and improves esophageal symptoms in the majority of SSc patients with esophageal involvement. Furthermore, buspirone exerts a greater beneficial effect on patients with less severely affected esophageal function as detected on chest CT, suggesting a therapeutic role mainly in patients with earlier or less severe involvement. Although further evaluation in placebo-controlled studies is warranted, buspirone could potentially be given under observation for objective improvement in all patients with SSc who report reflux symptoms, despite undergoing standard treatment.

Abbreviations

5-HT:

5-hydroxytryptamine

CT:

computed tomography

GERD:

gastroesophageal reflux disease

HRM:

high resolution manometry

IRP:

integrated relaxation pressure

LES:

lower esophageal sphincter

SSc:

systemic sclerosis

VAS:

visual analog scale

References

  1. 1.

    Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007;117:557–67.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Clements PJ, Becvar R, Drosos AA, Ghattas L, Gabrielli A. Assessment of gastrointestinal involvement. Clin Exp Rheumatol. 2003;21 Suppl 29:S15–8.

    CAS  PubMed  Google Scholar 

  3. 3.

    Ebert EC. Esophageal disease in scleroderma. J Clin Gastroenterol. 2006;40:769–75.

    Article  PubMed  Google Scholar 

  4. 4.

    Ntoumazios SK, Voulgari PV, Potsis K, Koutis E, Tsifetaki N, Assimakopoulos DA. Esophageal involvement in scleroderma: gastroesophageal reflux, the common problem. Semin Arthritis Rheum. 2006;36:173–81.

    Article  PubMed  Google Scholar 

  5. 5.

    Sallam H, McNearney TA, Chen JD. Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther. 2006;23:691–712.

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Karamanolis G, Panopoulos S, Karlaftis A, Denaxas K, Kamberoglou D, Sfikakis PP, Ladas SD. Beneficial effect of the 5-HT1A receptor agonist buspirone on esophageal dysfunction associated with systemic sclerosis: a pilot study. United Eur Gastroenterol J. 2015;3:266–71.

    CAS  Article  Google Scholar 

  7. 7.

    Hempfling C, Neuhuber WL, Worl J. Serotonin-immunoreactive neurons and mast cells in the mouse esophagus suggest involvement of serotonin in both motility control and neuroimmune interactions. Neurogastroenterol Motil. 2012;24:e67–78.

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Blonski W, Vela MF, Freeman J, Sharma N, Castell DO. The effect of oral buspirone, pyridostigmine, and bethanechol on esophageal function evaluated with combined multichannel esophageal impedance-manometry in healthy volunteers. J Clin Gastroenterol. 2009;43:253–60.

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Di Stefano M, Papathanasopoulos A, Blondeau K, Vos R, Boecxstaens V, Farré R, et al. Effect of buspirone, a 5-HT1A receptor agonist, on esophageal motility in healthy volunteers. Dis Esophagus. 2012;25:470–6.

    Article  PubMed  Google Scholar 

  10. 10.

    van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747–55.

    Article  PubMed  Google Scholar 

  11. 11.

    Geeraerts B, Vandenberghe J, Van Oudenhove L, Gregory LJ, Aziz Q, Dupont P, et al. Influence of experimentally induced anxiety on gastric sensorimotor function in humans. Gastroenterology. 2005;129:1437–44.

    Article  PubMed  Google Scholar 

  12. 12.

    de Bortoli N, Martinucci I, Savarino E, Bellini M, Bredenoord AJ, Franchi R, et al. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they? Neurogastroenterol Motil. 2014;26:28–35.

    Article  PubMed  Google Scholar 

  13. 13.

    Pitrez EH, Bredemeier M, Xavier RM, Capobianco KG, Restelli VG, Vieira MV, et al. Oesophageal dysmotility in systemic sclerosis: comparison of HRTC and scintigraphy. Br J Radiol. 2006;79:719–24.

    CAS  Article  Google Scholar 

  14. 14.

    Breedenoord AJ, Fox M, Kahrilas PJ, Pandolfino JE, Schwizer W, Smout AJ, International High Resolution Manometry Working Group. Chicago classification criteria of esophageal motility disorders defined in high resolution esophageal pressure topography. Neurogastroenterol Motil. 2012;24 Suppl 1:57–65.

    Article  Google Scholar 

  15. 15.

    Gao F, Liao D, Drewes AM, Gregersen H. Modelling the elastin, collagen and smooth muscle contribution to the duodenal mechanical behaviour in patients with systemic sclerosis. Neurogastroenterol Motil. 2009;21:914–e68.

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    McNearney TA, Sallam HS, Hunnicutt SE, Doshi D, Wollaston DE, Mayes MD, Chen J. Gastric slow waves, gastrointestinal symptoms and peptides in systemic sclerosis patients. Neurogastroenterol Motil. 2009;21:1269–e120.

    Article  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Loane C, Politis M. Buspirone: what is it all about? Brain Res. 2012;1461:111–8.

    CAS  Article  PubMed  Google Scholar 

  18. 18.

    Vonk MC, Van Die CEV, Snoeren MM, Bhansing KJ, van Riel PL, Fransen J, van den Hoogen FH. Oesophageal dilatation on high-resolution computed tomography scan of the lungs as a sign of scleroderma. Ann Rheum Dis. 2008;67:1317–21.

    CAS  Article  PubMed  Google Scholar 

  19. 19.

    Pandey AK, Wilcox P, Mayo JR, Moss R, Ellis J, Brown J, et al. Oesophageal dilatation on high-resolution CT chest in systemic sclerosis: What does it signify? J Med Imag Radiat Oncol. 2011;55:551–5.

    Article  Google Scholar 

  20. 20.

    Nguyen C, Ranque B, Baubet T, Bérezné A, Mestre-Stanislas C, Rannou F, et al. Clinical, functional and health-related quality of life correlates of clinically significant symptoms of anxiety and depression in patients with systemic sclerosis: a cross-sectional survey. PLoS One. 2014;9:e90484.

    Article  PubMed  PubMed Central  Google Scholar 

  21. 21.

    Malcarne VL, Fox RS, Mills SD, Gholizadeh S. Psychosocial aspects of systemic sclerosis. Curr Opin Rheumatol. 2013;25:707–13.

    Article  PubMed  Google Scholar 

  22. 22.

    Khanna D, Hays RD, Maranian P, Seibold JR, Impens A, Mayes MD, et al. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum. 2009;61(9):1257–63.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

There is no funding for the manuscript.

Authors’ contributions

GPK and PPS: conception and design, analysis and interpretation of the data, drafting of the article, and critical revision of the article for important intellectual content. SP: analysis and interpretation of the data, statistical analysis, and critical revision of the article for important intellectual content. KD, AK, AZ, and DK: analysis and interpretation of the data and critical revision of the article for important intellectual content. SLD: conception and design and critical revision of the article for important intellectual content. All authors approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Author information

Affiliations

  1. Academic Department of Gastroenterology, “Laiko” Hospital, Athens Medical School National and Kapodistrian University, Athens, Greece
    • George P. Karamanolis
    • , Konstantinos Denaxas
    • , Anastasios Karlaftis
    • , Dimitrios Kamberoglou
    •  & Spiros D. Ladas
  2. Joint Academic Rheumatology Programme, Athens Medical School National and Kapodistrian University, Athens, Greece
    • Stylianos Panopoulos
    • , Alexandra Zorbala
    •  & Petros P. Sfikakis
Authors
  1. George P. Karamanolis
    View author publications
    You can also search for this author in
  2. Stylianos Panopoulos
    View author publications
    You can also search for this author in
  3. Konstantinos Denaxas
    View author publications
    You can also search for this author in
  4. Anastasios Karlaftis
    View author publications
    You can also search for this author in
  5. Alexandra Zorbala
    View author publications
    You can also search for this author in
  6. Dimitrios Kamberoglou
    View author publications
    You can also search for this author in
  7. Spiros D. Ladas
    View author publications
    You can also search for this author in
  8. Petros P. Sfikakis
    View author publications
    You can also search for this author in

Corresponding author

Correspondence to George P. Karamanolis.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Karamanolis, G.P., Panopoulos, S., Denaxas, K. et al. The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: a 4-week, open-label trial. Arthritis Res Ther 18, 195 (2016). https://doi.org/10.1186/s13075-016-1094-y

Download citation

Keywords

  • Scleroderma
  • Buspirone
  • Esophageal motility
  • Reflux symptoms

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us